Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax (2022)
- Authors:
- USP affiliated authors: PONTES, LORENA LÔBO DE FIGUEIREDO - FMRP ; REGO, EDUARDO MAGALHÃES - FM ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; LIMA, KELI CRISTINA DE - FM ; VICARI, HUGO PASSOS - ICB ; SILVA, JEAN CARLOS LIPRERI DA - ICB
- Unidades: FMRP; FM; ICB
- DOI: 10.1016/j.htct.2021.01.004
- Subjects: FARMACOLOGIA; LEUCEMIA MIELOIDE AGUDA; APOPTOSE; MEDICAMENTO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: São José do Rio Preto
- Date published: 2022
- Source:
- Título do periódico: Hematology, Transfusion and Cell Therapy
- ISSN: 2531-1387
- Volume/Número/Paginação/Ano: v. 44, n. 1, p. 124-127, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-nd
-
ABNT
LIMA, Keli Cristina de et al. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2021.01.004. Acesso em: 29 maio 2024. , 2022 -
APA
Lima, K. C. de, Vicari, H. P., Carlos, J. A. E. G., Silva, J. C. L. da, Pontes, L. L. de F., Rego, E. M., & Machado Neto, J. A. (2022). Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.htct.2021.01.004 -
NLM
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 maio 29 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004 -
Vancouver
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 maio 29 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004 - Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia
- ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia
- Cellular and molecular effects of Eribulin in preclinical models of hematologic neoplasms
- STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells
- CDC7 (cell division cycle 7)
- Synthetic cyclopenta[b]indoles exhibit antineoplastic activity by targeting microtubule dynamics in acute myeloid leukemia cells
- Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms
- Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models
- Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia
- Exploring redox vulnerabilities in JAK2V617F-positive cellular models
Informações sobre o DOI: 10.1016/j.htct.2021.01.004 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | Obatoclax_reduces_cell_vi... | Direct link | |
| 003025145.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
